No Data
Catalyst Watch: Eyes on Tech With Apple, Amazon, Alphabet, and Meta Reporting
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Buy Recommendation for Biomea Fusion: Promising Clinical Developments of Icovamenib in Diabetes Treatment
Express News | Biomea Fusion Announces Approval of “Icovamenib” as International Nonproprietary Name for Bmf-219
Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday